Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). The product has recently been approved in the US and Canada.
Subscribe to our email newsletter
Meda said that it markets a higher strength (5%) of imiquimod in Europe under the trademark Aldara. In 2009, sales of Aldara were approximately 500 MSEK.
3,75% imiquimod can be used on a larger treatment area, it is once-daily and more tolerable due to the decreased concentration. The patent for this novel imiquimod formulation is pending.
Graceway Pharma is continuing its development program around 3,75% imiquimod. Meda has exclusive rights to follow-up products based on the imiquimod substance.
In consideration for exclusive European rights for 3,75% imiquimod, Meda is expected to pay Graceway Pharma an undisclosed up-front and a single digit royalty on net sales. No milestones payments will be due for 3,75% imiquimod.
Anders Lonner, CEO at Meda, said: “We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod.”